Clinical Trials Browser

Phase 2/3 × Neurofibrosarcoma × Imatinib Mesylate × Clear all

NCT00427583 2012-08-07

Imatinib Mesylate Treatment of Patients With Malignant Peripheral Nerve Sheath Tumors

Phase 2/3 Terminated

Neurofibromatoses, Nerve Sheath Neoplasms, Neurofibrosarcoma